Quetiapine |
| رقم الكتالوجGC14167 |
Quetiapine is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine is an atypical antipsychotic used to treat schizophrenia, bipolar disorder, and major depressive disorder.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 111974-69-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quetiapine is a 5-HT receptors agonist with a pEC50 of 4.77 for human 5-HT1A receptor. Quetiapine is a dopamine receptor antagonist with a pIC50 of 6.33 for human D2 receptor. Quetiapine is an atypical antipsychotic used to treat schizophrenia, bipolar disorder, and major depressive disorder[1].
Quetiapine (1, 10μM; 48h) causes cell cycle exit and promotes cell differentiation in primary oligodendrocyte cultures[2].Quetiapine (10, 20, 50μg/mL; 12h) treated had significantly lower levels of MDA and significantly higher activities of SOD and GSH-Px[3].Quetiapine (<100μM; 24h) has no significant effect on cell viabilities[4].
Quetiapine (400 mg/mL; surface application; 0, 6, 12, 24h) treatment significantly reduced skin thickening, erythema and edema, and inflammation caused by UVB irritation. In addition, Quetiapine treatment increased the activity of antioxidant enzymes, including superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px), while reducing the production of the oxidised lipid malondialdehyde (MDA)[3].Quetiapine (10, 30, 100mg/kg; po; bid; 28d) elicited a statistically significant, dose-dependent decrease in METH-induced hyperlocomotion 0.5h after administration. There were Quetiapine-induced, dose-dependent decreases in locomotor activity at 8 and 12h[4].
References:
[1].Cross A J, Widzowski D, Maciag C, et al. Quetiapine and its metabolite norQuetiapine: translation from in vitro pharmacology to in vivo efficacy in rodent models[J]. British journal of pharmacology, 2016, 173(1): 155-166.
[2].Mi G, Wang Y, Ye E, et al. The antipsychotic drug Quetiapine stimulates oligodendrocyte differentiation by modulating the cell cycle[J]. Neurochemistry International, 2018, 118: 242-251.
[3]. Xu P, Zhang M, Wang X, et al. Antioxidative effect of Quetiapine on acute ultraviolet-B-induced skin and HaCaT cell damage[J]. International Journal of Molecular Sciences, 2018, 19(4): 953.
[4] Kondo M A, Tajinda K, Colantuoni C, et al. Unique pharmacological actions of atypical neuroleptic Quetiapine: possible role in cell cycle/fate control[J]. Translational psychiatry, 2013, 3(4): e243-e243.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *